1. [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)]
- Author
-
A, Feyaerts, L, Stainier, M C, Nollevaux, P, De Groote, F, Lorge, R, Opsomer, F X, Wese, J P, Cosyns, and P, Van Cangh
- Subjects
Male ,Prostatectomy ,Antineoplastic Agents, Hormonal ,Prostatic Neoplasms ,Adenocarcinoma ,Middle Aged ,Prostate-Specific Antigen ,Disease-Free Survival ,Survival Rate ,Chemotherapy, Adjuvant ,Risk Factors ,Lymphatic Metastasis ,Disease Progression ,Humans ,Lymph Node Excision ,Neoplasm Recurrence, Local ,Follow-Up Studies ,Neoplasm Staging ,Retrospective Studies - Abstract
Lymph node metastases are rarely detected during radical prostatectomy (55/647 patients in our series or 8.5%) and several authors consider that lymphadenectomy is unnecessary in most cases. Criteria based on clinical stage, PSA and tumor grade have been elaborated in order to avoid pelvic lymph node dissection in a low risk population. It is commonly admitted that patients with clinically localized prostate cancer, a PSA level10 ng/ml, and a Gleason score7 could be spared a pelvic lymphadenectomy. In our series, these patients account for 12% of positive nodes. The best treatment for prostate cancer patients with a nodal disease is controversial. We compare the evolution of two groups of patients: radical prostatectomy alone or combined with an immediate adjuvant hormonal treatment. We observe a difference between the two groups for biological progression (PSA failure) but not yet for clinical progression nor for survival as our mean follow-up in only 6 years.
- Published
- 1998